MedTrace Logo

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

NCT06928246 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-05-04

No results posted yet for this study

Summary

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

Onabotulinum Toxin Type A - Phase 1b

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.

DRUG

Onabotulinum Toxin Type A - Phase 2

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.

Sponsors & Collaborators

  • Almirall, S.A.

    collaborator INDUSTRY

  • Daniel Kaplan

    lead OTHER

Principal Investigators

  • Daniel Kaplan, MD, PhD · University of Pittsburgh

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-17
Primary Completion
2026-12-15
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06928246 on ClinicalTrials.gov